Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Наслов
Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks
Идентификатор
/unibl/sci/idNaucniRad:36015
Тип
Пронађите сличне уносеAcademic Article
Датум
Пронађите сличне уносе2016-09
Библиографски цитат
LJ. Božić, Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks, STED Journal, Sep, 2016
Је дио
Пронађите сличне уносеSTED Journal
Пронађите сличне уносе2637-2150
Листа аутора
Position: 138345 (12 views)